{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:11:30Z","timestamp":1779923490486,"version":"3.53.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.cgh.2021.01.026","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T11:24:20Z","timestamp":1611314660000},"page":"438-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Racila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bourliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George V.","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Chokkalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issah","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.01.026_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.01.026_bib3","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.3748\/wjg.v25.i40.6094","article-title":"Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: a retrospective study","volume":"25","author":"Colussi","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.01.026_bib4","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/ajg.2016.99","article-title":"An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens","volume":"111","author":"Younossi","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.01.026_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2016.10.037","article-title":"Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis","volume":"15","author":"Younossi","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.01.026_bib6","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/hep.27161","article-title":"Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens","volume":"59","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.01.026_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/liv.12886","article-title":"The impact of ledipasvir\/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study","volume":"36","author":"Younossi","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2021.01.026_bib8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/apt.13269","article-title":"The patient's journey\u00a0with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life","volume":"42","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.01.026_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MPG.0000000000001754","article-title":"Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir","volume":"66","author":"Younossi","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2021.01.026_bib10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/liv.13650","article-title":"The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C","volume":"38","author":"Younossi","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2021.01.026_bib11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/jvh.12965","article-title":"Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection","volume":"25","author":"Younossi","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2021.01.026_bib12","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/liv.14171","article-title":"Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: the impact of hepatitis B and C viral replication","volume":"39","author":"Younossi","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2021.01.026_bib13","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jval.2018.01.006","article-title":"French patients with hepatitis C treated with direct-acting antiviral combinations: the effect on patient-reported outcomes","volume":"21","author":"Cacoub","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2021.01.026_bib14","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/liv.13462","article-title":"Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the ASTRAL-5 study","volume":"37","author":"Younossi","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2021.01.026_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/infdis\/jiv005","article-title":"Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes","volume":"212","author":"Younossi","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cgh.2021.01.026_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","article-title":"Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial","volume":"1","author":"Younossi","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.01.026_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/cid\/ciz243","article-title":"Not achieving sustained viral eradication of hepatitis C virus after treatment leads to worsening patient-reported outcomes","volume":"70","author":"Younossi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cgh.2021.01.026_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/liv.13900","article-title":"Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C","volume":"39","author":"Younossi","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2021.01.026_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.cgh.2021.01.026_bib20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jval.2016.02.005","article-title":"Performance and validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C","volume":"19","author":"Younossi","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2021.01.026_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.cgh.2021.01.026_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/A:1012588218728","article-title":"Interpreting SF-36 summary health measures: a response","volume":"10","author":"Ware","year":"2001","journal-title":"Qual Life Res"},{"key":"10.1016\/j.cgh.2021.01.026_bib23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jval.2017.10.005","article-title":"Prediction of health utility scores in patients with chronic hepatitis C using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV)","volume":"21","author":"Stepanova","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2021.01.026_bib24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11136-008-9332-7","article-title":"The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ)","volume":"17","author":"Schulz","year":"2008","journal-title":"Qual Life Res"},{"key":"10.1016\/j.cgh.2021.01.026_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11894-012-0301-5","article-title":"Quality of life in cirrhosis","volume":"15","author":"Loria","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.cgh.2021.01.026_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.01.026_bib27","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-118-8-199304150-00009","article-title":"Measuring health-related quality of life","volume":"118","author":"Guyatt","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2021.01.026_bib28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cgh.2019.07.047","article-title":"Long-term benefits of sustained virologic response for patient-reported outcomes in patients with chronic hepatitis C virus infection","volume":"18","author":"Younossi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:37:44Z","timestamp":1761543464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1542356521000768"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.01.026","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}